During the past decade, Pace Dermatology Associates conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 1 clinical trials were completed, i.e. on average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 1 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Pace Dermatology Associates" are "Dermatitis, Atopic" (2 trials). Many other conditions were trialed in "Pace Dermatology Associates" in a lesser frequency.

Most popular intervention types in "Pace Dermatology Associates" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (2 trials), "Abrocitinib 100 mg" (1 trials), "Abrocitinib 200 mg" (1 trials), "PF-04965842 100 mg" (1 trials) and "PF-04965842 200 mg" (1 trials). Other intervention names were less common.

The vast majority of trials in "Pace Dermatology Associates" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Pace Dermatology Associates". undefined are not yet recruiting, undefined are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Pace Dermatology Associates, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Pace Dermatology Associates, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".